Priya Marwah

ORCID: 0000-0001-7440-2502
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hemoglobinopathies and Related Disorders
  • Hematopoietic Stem Cell Transplantation
  • Pharmacovigilance and Adverse Drug Reactions
  • Blood groups and transfusion
  • Ethics and Legal Issues in Pediatric Healthcare
  • Hepatitis B Virus Studies
  • Central Venous Catheters and Hemodialysis
  • Renal Transplantation Outcomes and Treatments
  • Prenatal Screening and Diagnostics
  • Poisoning and overdose treatments
  • Pneumocystis jirovecii pneumonia detection and treatment
  • COVID-19 Clinical Research Studies
  • Complement system in diseases
  • Child and Adolescent Health
  • Sex work and related issues
  • COVID-19 and Mental Health
  • Pharmacological Effects and Toxicity Studies
  • Antibiotics Pharmacokinetics and Efficacy
  • Long-Term Effects of COVID-19
  • Metabolism and Genetic Disorders
  • Infant Development and Preterm Care
  • Kawasaki Disease and Coronary Complications
  • Immunodeficiency and Autoimmune Disorders
  • Preterm Birth and Chorioamnionitis
  • Erythrocyte Function and Pathophysiology

Mahatma Gandhi University
2022-2023

Gandhi Medical College & Hospital
2023

Mahatma Gandhi Institute of Medical Sciences
2022

University of Medical Sciences and Technology
2021

Borlaug Institute for South Asia
2013-2020

East Asia Institute
2014

Jagriti Innovations developed a collaboration tool in partnership with the Cure2Children Foundation that has been used by health professionals Italy, Pakistan, and India for collaborative management of patients undergoing bone marrow transplantation (BMT) thalassemia major since August 2008. This online open-access database covers data recording, analyzing, reporting besides enabling knowledge exchange, telemedicine, capacity building, quality assurance. As February 2014, over 2400 have...

10.1136/amiajnl-2013-002594 article EN cc-by-nc-nd Journal of the American Medical Informatics Association 2014-04-09

Matched-related bone marrow transplantation (BMT) may cure >80% of low-risk children with severe thalassemia (ST). Very long-term follow-up studies have shown how the standard busulfan-cyclophosphamide (BuCy) regimen be associated normalization health-related quality life, no second malignancies in absence chronic graft-versus-host disease, and fertility preservation many patients. However, because BuCy high rejection rates, some centers incorporate thiotepa (Tt) busulfan- or...

10.1182/bloodadvances.2016004119 article EN cc-by-nc-nd Blood Advances 2017-05-11

Thalassemias are the most common inherited genetic disorder in India and a major public health burden with bone marrow transplant (BMT) considered only established curative therapy. We describe outcomes for patients (n = 71) standard-risk thalassemia (liver size < 2 cm age <15 years), receiving BMT 6 low-cost start up centers Indian sub-continent from August-2013 to July-2016. Patients received HLA-matched sibling donor unmanipulated BMT. Conditioning was busulfan (14 mg/kg oral total over...

10.1016/j.phoj.2017.12.002 article EN cc-by-nc-nd Pediatric Hematology Oncology Journal 2017-12-01

Severe thalassemia syndromes (ST) are highly curable by bone marrow transplant (BMT), but rejection may still occur. We retrospectively analyzed our fully matched related donor transplants to establish if isolated splenomegaly is an independent risk factor for and this can be reduced modifying the conditioning protocol. In study, we compared rates between patients with without in 189 consecutive low-risk ST across 2 sequential regimens: regimen A (August 2013 December 2016): busulfan (14...

10.1016/j.bbmt.2020.06.013 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2020-06-24

Even though severe thalassemia is a preventable disease, over 100,000 new cases are born yearly, particularly in the Middle East and South-East Asia. Most of these children may not reach adulthood because long-term appropriate supportive care either inaccessible or unaffordable. Bone marrow transplantation (BMT) remains only available definitive cure success rates can be very high appropriately selected patients, i.e. low-risk younger with matched family donor. In circumstances BMT justified...

10.4081/thal.2013.s1.e42 article EN cc-by Thalassemia Reports 2013-03-26

Abstract Background Patients with tunneled central venous lines (CVL) may develop bloodstream infections which at times are difficult to control without line removal. Concomitant severe thrombocytopenia platelet transfusion refractoriness is often considered a major contraindication any procedure involving blood vessel. There very little literature on the clinical risks of removal in febrile pancytopenia patients. Procedure We analyzed complications and outcomes all our patients, total 52,...

10.1002/jha2.379 article EN cc-by eJHaem 2022-01-15

The present study has been carried out to determine the risk factors associated with recurrent febrile seizures. Thestudy was a hospital based prospective observational study. Risk of evaluated on basis cumulative analysis clinical profile all cases. Every child followed up for one year. In our recurrence seen in 34 (55.7%) subjects. Factors like age less than 1 year at first episode seizure, fever duration &amp;#60;24 hours and temperature time seizure &amp;#60; 102.2F had higher...

10.18231/j.pjms.2023.012 article EN cc-by-nc-sa Panacea Journal of Medical Sciences 2023-04-07

Objective: Coronavirus disease-19 (COVID-19) infection has quickly developed into a global pandemic. According to the available evidence, children appear be less likely afflicted and condition may severe, but things could change. Rapid deterioration enhancements in physiologic state are hallmark of pediatric community. Therefore, this study was conducted with aim demographic clinical parameters COVID patients. Methods: This hospital-based prospective retrospective during April 1st, 2020–July...

10.22159/ajpcr.2023v16i9.47885 article EN Asian Journal of Pharmaceutical and Clinical Research 2023-09-07

Purpose: Auto immune hemolyticanemia (AIHA) post allogeneic hematopoetic stem cell transplantation (HSCT) is a rare and still poorly understood complication.Detailed work on this complication are needed due to lack of prospective trials.Methods: This retrospective cohort study 7 patients with AIHA after HSCT in tertiary care Medical College Hospital from 2012 -2023.Results: The overall incidence was 3.93%.All transplants were performed for non -malignant condition.57.1 % the who developed...

10.21275/sr231126183730 article EN International Journal of Science and Research (IJSR) 2023-11-05

BackgroundSevere thalassemia syndromes (ST) are highly curable by BMT but rejection may occur in 5 to 30% of cases. Splenomegaly was shown increase the risk even low transplant setting our earlier review (https://ash.confex.com/ash/2017/webprogram/Paper104001.html).ObjectiveTo assess impact splenomegaly on and study effectiveness increased immunosuppression preparative regimen.MethodsWe compared outcomes patients with between two conditioning regimens: Our protocol (Regimen A) a more recent...

10.1016/j.bbmt.2018.12.170 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2019-02-01
Coming Soon ...